Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Sarcoma 1

Conditions

Wilms Tumor 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Bone Neoplasms 1Blast Crisis 1

Interventions

Gemcitabine 4pembrolizumab 3Docetaxel 3Cryosurgery 3Biopsy 3eribulin 2durvalumab 2balstilimab 2atezolizumab 2aflibercept 2Zoledronic Acid 2Trastuzumab 2Taxes 2Specimen Handling 2Radiotherapy 2Radiosurgery 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Letrozole 2Irinotecan 2Gene Expression Profiling 2Fulvestrant 2Cisplatin 2Blood Specimen Collection 2Bevacizumab 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Etanercept × Sarcoma × Clear all
NCT00127387 2012-06-26

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

The University of Texas Health Science Center at San Antonio

Phase 2/3 Terminated
54 enrolled
GenitourinarySarcomaThoracic

Bone Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡